Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TRICARE getting retroactive rebates

Executive Summary

Manufacturers of drugs dispensed through the TRICARE retail pharmacy program were subject to the ceiling price as of Jan. 28, 2008, and are therefore subject to a refund for the difference in price paid, the Department of Defense says in a March 17 final rule implementing provisions of the National Defense Authorization Act for 2008. Manufacturers may seek a waiver or compromise in the refund amount, but refund payments for utilization data from Jan. 28 through Dec. 31, 2008 are due May 26. Manufacturer groups submitted comments arguing against making the refund retroactive (1"The Pink Sheet," Sept. 29, 2008, p. 13)

You may also be interested in...



Retroactive TRICARE Retail Rebates Could Cause Trouble, PhRMA And BIO Say

BIO and PhRMA are urging the Department of Defense to back down from its proposal to make rebates for drugs filled through the TRICARE retail pharmacy program retroactive to January

Advanz Pharma Agrees Sale In Largest European Deal Since COVID-19 Pandemic

Three years after rebranding from Concordia, Advanz Pharma is to be swallowed up by European-focused private equity Nordic Capital.

Consumer Genome Sequencing Being Applied To Covid-19 New Variants In UK

The goal is to create a program which mass sequences SARS-CoV-2 samples in order to detect new variants, with £30m injected into the UK's hub for genomic sequencing in Cambridge.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel